Mid-Year Report

THE MCMANUS GROUP for GENENTECH

Firm
Client
Income
$90,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Comparative effectiveness provisions in S. 3, "Medicare Prescription Drug Price Negotiation Act of 2007" Clarification of scope of Medicaid rebates for physician-administered drugs in Deficit Reduction Act (P.L. 109-171). Opposition to repeal of non-interference provision in H.R. 4/S. 3, "Medicare Prescription Drug Price Negotiation Act of 2007."

LobbyistCovered position, as disclosed
JOHN MCMANUS N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4 (110th), S. 3 (110th)

Health Issues HCR

H.R. 1038, "Access to Life-Saving Medicine Act." S. 1695, "Biologics Price Competition and Innovation Act of 2007" H.R. 2900/S. 1082, Prescription Drug User Fee Act reauthorization

LobbyistCovered position, as disclosed
JOHN MCMANUS N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1038 (110th), H.R. 2900 (110th), S. 1082 (110th), S. 1695 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.